Лучшие больницы для «Diagnostic Surgery» в Хайдарабад, Индия

Cancer diagnosis is a multi-step process, but it is the histopathological confirmation of malignant tissue — obtained through diagnostic surgery — that forms the irreplaceable cornerstone of oncology care. Diagnostic surgery encompasses a spectrum of procedures designed not to cure cancer, but to procure an adequate tissue sample for pathological, immunohistochemical (IHC), molecular, and genomic analysis. The resulting data — including tumour type, grade, receptor status (e.g., ER/PR/HER2 in breast cancer, PD-L1 expression in lung cancer, microsatellite instability in colorectal cancer), and mutational profile (EGFR, ALK, KRAS, BRCA1/2) — determines whether a patient is a candidate for surgery, chemotherapy, targeted therapy, immunotherapy, or a combination approach.

• Patients with a radiologically identified mass, nodule, or lymphadenopathy on CT, MRI, PET-CT, or mammography that is suspicious for malignancy but lacks tissue confirmation
• Individuals with elevated tumour markers (CA-125, CEA, AFP, PSA, CA 19-9) without a histologically confirmed primary site, requiring diagnostic surgery to identify the origin
• Patients presenting with unexplained ascites, pleural effusion, or peritoneal deposits where cytology alone is non-diagnostic, necessitating laparoscopic peritoneal biopsy or thoracoscopic pleural biopsy
• Patients with early-stage breast cancer, melanoma, or head-and-neck squamous cell carcinoma requiring sentinel lymph node biopsy (SLNB) for accurate N-staging prior to definitive surgery or radiation planning
• Individuals with suspected lymphoma (Hodgkin or non-Hodgkin) where a core-needle biopsy has been inconclusive and an excisional lymph node biopsy is required for architectural assessment
• +4 more

PERCUTANEOUS IMAGE-GUIDED BIOPSY (Minimally Invasive — First-line where feasible) Ultrasound-guided core-needle biopsy (CNB): Used for palpable or sonographically visible masses in the breast, thyroid, soft tissue, liver, and superficial lymph nodes. An 14–18 gauge automated biopsy gun acquires 3–5 cores; outpatient procedure under local anaesthesia with same-day discharge. Diagnostic accuracy >93% for breast lesions. CT-guided percutaneous biopsy: Preferred for deep-seated pulmonary nodules, retroperitoneal masses, bone lesions, and adrenal tumours. Coaxial biopsy technique allows multiple cores through a single pleural or peritoneal pass, reducing pneumothorax or haemorrhage risk. Accuracy for lung lesions: 90–95%. MRI-guided biopsy: Reserved for lesions only visible on MRI (e.g., MRI-only detected breast lesions, prostate lesions targeted via MRI-TRUS fusion biopsy using the UroNav or Artemis fusion platform). Multiparametric MRI (mpMRI) followed by targeted fusion biopsy has replaced random 12-core TRUS biopsy as the standard for clinically significant prostate cancer detection. Endoscopic ultrasound (EUS)-guided fine-needle aspiration/biopsy (FNA/FNB): Gold standard for pancreatic masses, submucosal GI lesions, and perigastric/perirectal lymph nodes. The 22–25 gauge FNA needle or 20–22 gauge FNB (Franseen/SharkCore) needle acquires tissue with rapid on-site evaluation (ROSE) by a cytopathologist to confirm adequacy. Endobronchial ultrasound (EBUS)-guided transbronchial needle aspiration (TBNA): Minimally invasive mediastinal staging tool replacing mediastinoscopy in most N2/N3 lung cancer staging scenarios. Provides real-time ultrasound guidance to biopsy mediastinal and hilar lymph node stations (2R, 2L, 4R, 4L, 7, 10, 11). Sensitivity for malignant mediastinal nodes: 89–93%.

SURGICAL BIOPSY TECHNIQUES (Open or Minimally Invasive) Excisional biopsy: Complete removal of a suspicious lymph node or small soft-tissue mass for intact architectural histopathological assessment. Preferred for suspected lymphoma where nodal architecture is diagnostically critical (Reed-Sternberg cells in Hodgkin lymphoma require intact follicular architecture). Performed under local or general anaesthesia. Incisional biopsy: Partial sampling of a large, unresectable mass; used for large sarcomas or unresectable tumours where the biopsy tract must be planned along the future resection axis to avoid tumour seeding of adjacent compartments. Sentinel Lymph Node Biopsy (SLNB): Current standard of care in early-stage breast cancer (T1-T2 N0) and melanoma. The sentinel node is identified using a dual-mapping technique combining 99mTc-labelled nanocolloid (radioisotope lymphoscintigraphy with gamma probe detection) and blue dye (patent blue or isosulfan blue), or increasingly with indocyanine green (ICG) fluorescence imaging using near-infrared (NIR) cameras (SPY-PHI or Fluobeam system). ICG-only mapping is now preferred at many centres due to superior visualisation and avoidance of radioactive material handling. Intraoperative frozen section or one-step nucleic acid amplification (OSNA) assay determines lymph node status within 30–40 minutes, permitting immediate axillary lymph node dissection (ALND) if macro-metastasis is confirmed. Diagnostic Laparoscopy with peritoneal washings: Critical staging procedure for gastric, ovarian, endometrial, and colorectal cancers before planned cytoreductive surgery or radical resection. The peritoneal carcinomatosis index (PCI) is scored laparoscopically across 13 abdominal regions (0–39 scale). PCI ≥20 in colorectal cancer or ≥10 in gastric cancer typically precludes curative resection. Peritoneal washings are sent for cytological analysis; positive cytology upstages gastric and ovarian cancer. VATS (Video-Assisted Thoracoscopic Surgery)-guided biopsy: Minimally invasive thoracoscopic approach for pleural biopsies, lung wedge resections (for indeterminate pulmonary nodules), and mediastinal mass biopsies not accessible via EBUS. Three 5–10 mm ports; hospital stay 2–3 days; significantly reduced morbidity versus open thoracotomy. Robotic-assisted staging procedures: The da Vinci Xi and Versius robotic platforms are used at premier centres in India (Tata Memorial, Apollo, Fortis) and the UAE (Cleveland Clinic Abu Dhabi, Mediclinic City Hospital Dubai) for complex diagnostic staging laparoscopies, robotic mediastinal staging, and robotic-assisted SLNB in anatomically challenging cases. Advantages include 3D magnification, tremor filtration, and 540° EndoWrist articulation enabling precise dissection in confined anatomical spaces.

MOLECULAR AND GENOMIC PATHOLOGY (Post-Biopsy) All tissue obtained undergoes haematoxylin-and-eosin (H&E) histopathology plus IHC panel. Advanced centres offer next-generation sequencing (NGS) panels (e.g., FoundationOne CDx, Oncomine Dx Target Test, TruSight Oncology 500) for comprehensive genomic profiling, enabling identification of actionable mutations for targeted therapy (e.g., osimertinib for EGFR-mutant NSCLC, olaparib for BRCA-mutant breast/ovarian cancer, entrectinib for NTRK fusion-positive tumours). Liquid biopsy (circulating tumour DNA via Guardant360 or FoundationOne Liquid CDx) may complement but does not replace surgical tissue biopsy for initial diagnosis.

PRE-OPERATIVE PHASE (Days 1–5 in destination country)

Day 1 — Arrival and Oncology Consultation: GAF Healthcare coordinates airport pickup and hotel check-in. The patient attends a consultation with the lead oncologist or surgical oncologist, who reviews all prior imaging (CT, MRI, PET-CT), pathology reports, and tumour marker data. The most appropriate diagnostic surgical approach is selected based on lesion location, accessibility, and required tissue volume for planned molecular testing.

Day 2–3 — Pre-Operative Investigations: Blood work (CBC, coagulation panel, metabolic panel, tumour markers), ECG, and anaesthesia fitness assessment are completed. For thoracic procedures, pulmonary function tests (PFTs) and echocardiography may be added. Anti-coagulants (warfarin, DOACs, aspirin) are bridged or held per protocol. Patients are counselled on the procedure, anaesthesia plan, and expected histopathology turnaround time.